BRISBANE, Australia, Dec. 3 /PRNewswire/ -- Implicit Bioscience has appointed Helen Roberts as Director of Business Development. Helen brings to Implicit over 18 years experience in the biotechnology and pharmaceutical sector in a variety of senior commercial roles. Her responsibilities have encompassed corporate and business development, leadership of sales, marketing and product development teams, strategic planning and public affairs.
Most recently she served as Director, Clinical and Commercial Programs at Brisbane-based Agenix where she was responsible for strategic clinical and regulatory oversight, business development and commercialization planning for their in vivo clot-imaging program.
Prior to that she worked with a number of top tier firms including Merck, Bayer and American Cyanamid (now Wyeth) in roles of increasing scope and with responsibility for flagship brands, both in Australia and overseas. Helen graduated with a Bachelor of Applied Science in 1984 and earned her MBA from University of Technology, Sydney in 1995.
About Implicit Bioscience
Implicit Bioscience is a privately-funded development stage biopharmaceutical company with operations in Brisbane, Australia and Seattle, Washington. The company has major strengths in immunology, peptide chemistry and drug development, and is focused on the identification and development of new therapies for infectious disease. Its current activities are focused on the development of the immunomodulator oglufanide disodium in hepatitis C and for biodefense applications.
CONTACT: Dick Haiduck, Chief Business Officer of Implicit Bioscience,
+1-650-851-3133, dick.haiduck@implicitbiosicence.com; or Garry Redlich, CEO
of Implicit Bioscience Pty Ltd, +61 (0) 417 728 583,
garry.redlich@implicitbioscience.com
Web site: http://www.implicitbioscience.com/
